What it sells
Scaling Genomic AI for Embryo Selection
Business model breakdown
Buyer: who owns the budget?
Patients paying directly (HSA/FSA eligible, Affirm financing).
Trigger: what makes them buy now?
UnverifiedRecurrent pregnancy loss or infertility with unexplained cause.
Workflow: what inputs become what output?
At-home saliva/cheek swab kit, lab sequencing of 750+ genes, report with genetic counselor session; embryo reports for IVF.
Economics: what it saves and how it charges
Direct-to-consumer test sales; full refund if no reportable finding.
Distribution: how it reaches customers
Direct online checkout, 2-minute quiz, referral program, content/publisher collaborations.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Fall 2024 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.